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A b s t r a c t  
The present work deals with the aceclofenac pellets prepared by suspension layering technique, 
using sugar spheres with various concentrations of ethyl cellulose and kollicoat SR-30D as enteric 
coating materials. Prepared pellets were evaluated for physical characteristics which showed 
excellent flow properties. Formulation F8 with the maximum drug content of 97.17% showed a 
prolonged in vitro drug release till 10hr when compared with the pure drug. The optimized 
formulation showed particle size distribution of 546øm.Further stability studies performed according 
to the ICH guidelines also showed no change in the drug content and property during the shelf life of 
3months at prescribed RH and temperature conditions. 
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Introduction 
The delivery systems are designed to achieve a prolonged 
therapeutic effect by continuously releasing medication over an 
extended period of time after administration of single dose. To 
obey this concept sustained drug delivery is one of the routes to 
reduce the dose frequency and side effects [1]. From a 
pharmaceutical practical view, various categories of polymers are 
currently present [2]. So, sustain release dosage forms provide a 
better control of plasma drug levels, less dosage frequency, less 
side effect, increased efficacy and constant delivery [3]. Among the 
different approaches for sustained delivery of drugs pellets has 
drawn more attention since they are spherical, free-flowing 
granules with a narrow size distribution, typically varying between 
500 and 1500 μm in size for pharmaceutical applications. They are 
formed as a result of a pelletization process which is an 
agglomeration process that converts fine powders or granules of 
bulk drugs and excipients into small, free-flowing, spherical or 
semi-spherical units [4]. 
The advantages for pellets are, it permits the combination of 
different release rates of the same drug in a single dosage form , 
controlled release technology , invariably maximize drug 
absorption, less susceptible to dose dumping and it can be used 
for  masking the taste of bitter drugs [5,6,7]. 
In the present work suspension layer method is chosen to 
formulate the aceclofenac pellets. Solution or suspension layering 
involves the deposition of successive layers of solution and/or 
suspensions of drug substances and binder over the starter non-
peril seeds, which is an inert material or crystals or granules of the 
same drug. In fact the coating process is applicable to solution or 
suspension [5]. The coating pans, fluidized beds, centrifugal  
 
 
granulators, Wurster coaters have been used successively to 
manufacture pellets by this method [8]. 
Aceclofenac (2-[(2, 6-dichlorophenyl) amine] phenylacetoxyacetic 
acid) is a phenyl aceticacid derivative [9], non-steroidal anti-
inflammatory drug (NSAID) with wider therapeutic use viz., 
treatment of various conditions like ankylosing spondylitis [10, 11], 
rheumatoid arthritis [12] osteoarthritis [13]. It has less 
gastrointestinal complications [14]. Aceclofenac has daily dose of 
200 mg divided in to two doses to maintain the plasma 
concentration. The short biological half-life about 4 hr and dosing 
frequency more than one per day  with low aqueous solubility and 
as a consequence, has low oral bioavailability [15] makes 
aceclofenac an ideal candidate for sustained release. To reduce 
the frequency of administration and to improve patient compliance, 
a once-daily sustained release formulation of aceclofenac is 
desirable [16, 17]. 
In the present research work suspension layer method was 
adopted to coat the aceclofenac pellets using different polymers 
ethylcellulose, kollicoat SR-30D and HPMCK-4m. 
Materials and methods 
Materials 
Aceclofenac was provided by the Dynamed 
Pharmaceuticals, Hyderabad. Sugar spheres were purchased from 
the signet chemical corporation pvt Ltd, Mumbai. HPMCK-4m and 
ethyl cellulose were purchased from the Dow chemicals, Chennai. 
Kollicoat SR30D was provided by BASF pharma, Mumbai. All other 
materials and reagents were of analytical grade. 
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Drug-Excipients compatibility study 
The compatibility study of drug and excipients was done by using 
fourier transform infrared spectroscopy (FTIR). The FT-IR studies 
for drug, ethylcellulose, kollicoat Sr-30D drug+ethycelluclose, 
drug+kollicatSR-30D, drug+mixture of excipients were performed. 
The method used was drug mixed with KBr (100 times more 
amount than drug) and compressed into discs by applying a 
pressure of 5 tons for 5 min in a hydraulic press. The compressed 
disc was placed in the light path and the spectrum was obtained. 
Method of preparation 
Preparation of Drug-Containing Pellets 
Aceclofenac loaded pellets were prepared by layering a drug-
binder solution (10 % w/w) on to sugar spheres using a fluidized 
bed coater. Dispersion of aceclofenac and polyvinyl pyrollidone 
(PVP K - 30) was sprayed using the bottom spray mode. Layered 
beads were dried at 40oC for 5ă 10 min. The procedure was 
carried out in 3steps. 
Step-1: Drug coating   
1. Preparation of coating solution: 
 PVP K-30 was dissolved in Isopropyl alcohol, aceclofenac was 
dissolved in PVP K-    30solution. Talc was added to the above 
solution. A white milky solution was obtained, which was then 
passed through # 100 Sieve is called as primary solution. 
2. Primary coating on spheres 
 Sugar spheres were loaded in to fluidized bed drier [20] and coat 
the primary suspension to sugar spheres. The drug loaded pellets 
were collected. 
Step-2: Seal coating /barrier coating [21]. 
Preparation of barrier coating solution 
HPMCK-4m was dissolved in water on continuous stirring to 
prepare barrier coating solution.  
Coating of barrier solution: 
The collected pellets were loaded in to fluidized bed drier and 
coated with the above prepared solution by bottom spray mode 
[22]. 
Step-3: Enteric coating [21]  
Preparation of enteric coating solution 
The non aqueous solution of different polymeric concentrations 
ethyl cellulose and kollicoat SR 30 D i.e., in 
3%,6%,9%,12%concentrations were prepared separately. The 
solution was plasticized with tri ethyl citrate (10 wt%, based on the 
mass of the polymer). The non aqueous solvents contain the iso-
propyl alcohol (IPA). These are enteric coating solutions.  
Coating of enteric coating solution 
From the step -2 barrier coated pellets were taken and loaded in to 
fluidized bed drier. Then by using above enteric coated solution 
was sprayed on pellets and the pellets dried at 40oc for 10min. 
repeat the same procedure for different concentrations of prepared 
enteric coated solution.  
Totally 9 formulations were prepared and individual formula 
composition was given in table 4. 
Evaluation of formulated aceclofenac pellets 
Determination of bulk density and tapped density 
An accurately weighted quantity of the powder (W) was carefully 
poured into the granulated cylinder and the volume (Vo) was 
measured.  Then the graduated cylinder was closed with lid  and 
set into the density determination apparatus (bulk density 
apparatus) which was set for 500 taps,750 taps , and 1250 taps.  
After that the volume (Vf) was measured and continued the 
operation till the two consecutive readings were equal. The bulk 
density and the tapped density were calculated using the following 
formulas.  
Bulk Density ă W/Vo 
Tapped Density- W/Vf 
Where W- Weight of the powder 
Vo - Initial volume (s) 
Vf - Final volume. 
HausnerÊs ratio 
It indicates the flow properties of the powder and measured by the 
ratio of Tapped density to bulk density. The standard limits of 
hausnerÊs ratio given in table 3. 
HausnerÊs ratio= Tapped density /Bulk density. 
CarrÊs index 
The compressibility of powder was determined by CarrÊs 
compressibility index. The standard limits of carrÊs index was given 





Angle of repose  
The angle of repose of aceclofenac pellets were determined as 
follows The powder is allowed to fall over a paper on a horizontal 
surface through a funnel or an orifice kept at a certain convenient 
height a cylindrical tube open at both the ends is placed on a paper 
on a horizontal surface. The powder is then, poured in to the 
cylinder and the tube is gradually withdrawn without any shaking 
movements allowing the powder to from a heap on the horizontal 
surface. The height of heap formed and then the circumference of 
the base of the heap is drawn on the paper with the help of pencil. 
The radius of circle obtained is measured. The standard limit 
values were given table 1. 
Tanθ=h/r 
h=height of heap 
r=radius of the base of the heap 
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Particle size distribution 
This practice was done for the pellets obtained after functional 
coating to check average size of the pellets. 30g of the pellets were 
passed through series of sieves was placed (#16, #22, # 25 and 
#30). The machine was run for 5 minutes, all the sieves were taken 
out and retained granules were collected by respective sieve and 
the % retention of pellets by that sieve was calculated. Average 
particle size was determined. The results were shown in table 7. 
Friability test 
Friability is the loss of weight of pellets in the container/package, 
due to removal of fine particles from the surface. Roche Friabilator 
was used to measure the friability of the pellets. It was rotated at a 
rate of 25 rpm. 5 g pellets were weighed collectively and placed in 
the chamber of the friabilator. In the friabilator, the pellets were 
exposed to rolling, resulting from free fall of pellets within the 
chamber of the friabilator. After 100 rotations (4 min), the pellets 
were taken out from the friabilator and intact pellets were again 
weighed. Permitted percentage friability limit is 0.8%. The percent 
friability was determined using the following formula. 
 
                           Percent friability = (W1 ă W2) X 100  
                                                             W1 
Where W1 = weight of the pellets before test. W2 = weight of the 
pellets after test. 
Drug content estimation 
Weighed the pellets equivalent to 100 mg was crushed in mortar 
and transferred to 100 ml flask. The powder was dissolved in 3 ml 
of methanol and volume was made up with 3% SLS in pH 6.8 
phosphate buffer. The sample was mixed for 5 minutes, then it was 
filtered through Whatman filter paper. The filtered solution after 
appropriate dilution (1 ml to 10 ml) with 3% SLS in pH 6.8 
phosphate buffer were analyzed by validated UV 
spectrophotometric method at λmax 275nm. 
In Vitro dissolution studies 
The dissolution study was carried out using USP test apparatus ă 
II(paddle type  in pH 6.8 phosphate buffer along with 3%SLS as 
media to justify the dissolution media  to mimic the gastric intestinal 
media [27].  In this study, the pellets were placed in the dissolution 
medium (900 ml) with stirring speed set as 75 rpm. Samples (5 ml) 
with drawn at a time interval of 0.25, 0.50, 0.75, 1, 2, 4, 8, 10 
hours. The samples were withdrawn at predetermined time 
intervals were subsequently replaced with fresh media. Sample 
solutions were then filtered through 0.45μm membrane filters and 
the drug concentration was analyzed spectrophotometrically at 
275nm.The percentage drug release was plotted against time to 
determine the release profile.  
Stability Studies 
Optimised formulation were packed and stored in ICH certified 
stability chambers maintained at  
25ĈC and 60% RH   
40ĈC and 75% RH for three months.  
Scanning electron microscopy for the optimised 
formulation 
Morphological characterisation of the pellets was studied by the 
scanning electron micrograph in (JEOL JSM Model 5200).cross-
sectional view were obtained by cutting the pellets with a razor 
blade. The samples were coated to 200 A0 thickness with gold-
platinum using (placo model 3 sputter coater) prior to microscopy 
working distance of 20nm.a tilt of 00 and acclerating voltage of 15 
kv were the operating parameters. Photographs were taken within 
range of 20-500 magnification.  
Results and discussion 
Drug-excipients compatibility study 
The possible interactions for drug and excipients were investigated 
by FT-IR spectroscopy.  The results reveals that there is no 
appearance or disappearance of peaks which shows that the 
interaction between the drug and excipients were nil. Thus the 
compatibility of the drug and excipients was satisfactory. 
Flow properties of aceclofenac pellets 
The flow properties like bulk density, tapped density, carrÊs index, 
hausnerÊs ratio, angle of repose were evaluated for prepared 
pellets. The bulk density and tapped density of 9 formulations were 
in the range of 0.8035μ0.0021 to 0.8276μ0.0014 and 
0.8476μ0.0021 to 0.8858μ0.0018. The carrÊs index for all the 
formulations <10% shows excellent flow property. The hausnerÊs 
ratio were in the range of 1.0477μ0.0034 to 1.0927 μ0.0023, the 
angle of repose for F1 to F8 shows excellent flow property and F9 
shows a good flow. The results for all batches were shown in table 
5. Almost all the formulations show an excellent flow property. 
Friability 
The friability of the pellets were tested by using roche friabilator, 
the values were found to be below 0.4%, which shows that the 
pellets have desirable hardness. Friability (%) of all the batches is 
shown in table 6. From the table the formulation which showed 
least deviation from the standard was taken as the optimized 
formulation. 
Drug content 
The drug content of prepared pellets were found to be in the range 
of 95.50μ0.034 to 97.61μ0.08 for all the formulations. The 
formulation (F8) shows the maximum drug content hence this was 
taken as the optimized formulation. The drug content of all 
formulations was given in table 6. 
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In-vitro studies 
The in-vitro study of aceclofenac was carried out in USP type-II 
(paddle) apparatus in pH=6.8 phosphate buffer at 37μ0.5oc with 
stirring speed 75rpm.The in-vitro release was carried out for all the 
prepared pellets and compared with the pure drug. The pure drug 
aceclofenac shows the 40.23% release 3hr.The pellets coated with 
ethyl cellulose i.e.,F4 released the maximum of 87.23μ0.34 at 10hr 
where as F2released 93.31μ0.34 at 6hr, F3 released 92.23μ0.34 at 
8hr ,F5 showed a release of 85.51μ0.47 at 10 hr and then no 
further release was observed from the above formulations. Coming 
to pellets prepared with kollicoat SR-30D shows the maximum 
release for F8 with 96.43μ0.46 at 10 hrs, other formulations viz., F6 
shows 92.21μ0.24 at 6hr, F7 shows 90.21μ 0.55 at 8hrs, F9 
released a maximum of 87.41μ0.35 at 10hr.From the results of in-
vitro study F8 formulation was taken as the optimized among the 
other pellets since maximum release was observed upto 10hr. The 
results were shown in figure 1 and table 8(a) &8(b). 
 
 
Figure 1: In-vitro profile for Aceclofenac pellets with various 
concentration of a) ethyl cellulose and b) Kollicoat SR-30D. 
 
Though all the formulations resulted in similar fashion of release 
and flow characteristics for convenient purpose formulation F8 was 
taken for the particle size analysis and morphological studie 
Particle size analysis 
Sieve analysis was carried out for the formulation F8. From the 
result it was evident that most of the pellets were retained in 
sieve#20. The average diameter of pellet was found to be as 
545.6øm.  
Scanning electron microscope 
The surface morphology of optimized formulation was studied from 
SEM.  It was evident that all 
formulated pellets were spherical in shape with uniform size shown 
at low magnification, the more information about the surface 
characteristics of optimized pellets were obtained with increasing 
the magnification. The figure 2 with magnification at 150X shows 
the external morphology of kollicoat-SR30D shows more rough 
surface which is due to the density of the matrix and it justifies 
sustained action. The SEM micrographs were shown in figure 2. 
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Table 1: Standard limits for Angle of repose 
Angle of repose Flow property 
< 25o Excellent 
25-30o Good 
30-40o Average(addition of 0.2% Glident)
>40o Poor 
 
Table 2: Standard limit for carrÊs index 
Type of flow 
Limit 
  Excellent 
<10 
Good 
11 ă 15 
Fair 
16 ă 20 
Passable 
21 ă 25 
Poor 
26 ă 31 
Very poor 
32 ă 37 
Very very poor 
>38 
 













Table 4: Composition for formulation of Aceclofenac pellets 
 
 












Very very poor 
>1.60
Ingredients F1  F2 F3 F4 F5 F6 F7 F8 F9
Drug layering 
200 200 200 200 200 200 200 200 200 
Sugar spheres(20-25mesh) 
Aceclofenac (mg) 200 200 200 200 200 200 200 200 200
PVP K-30 (mg) 75 75 75 75 75 75 75 75 75
Barrier coating 
30 30 30 30 30 30 30 30 30 
HPMC K-4M(mg) 
Enteric coating 
- 3% 6% 9% 12% - - - - 
Ethyl Cellulose (%) 
Kollicoat SR 30 D(%) - - - - - 3% 6% 9% 12%
Triethyl citrate(mg) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Isopropyl alcohol Qs qs qs qs Qs qs qs qs qs
Talc (mg) 8 8 8 8 8 8 8 8 8
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Table 5: physico chemical properties of Aceclofenac pellets 
Formulation code Bulk density (g/cc) Tapped density 
(g/cc) 





F1 0.8158μ0.0009 0.8830μ0.0012 24.524μ0.011 7.610μ0.0011 1.080μ0.0061 
F2 0.8276μ0.0014 0.8807μ0.0012 25.236μ0.012 5.310μ0.0009 1.064μ0.0054 
F3 0.8045μ0.0012 0.8691μ0.0006 
22.127μ0.030 7.432μ0.0013 1.080μ0.0033 
F4 0.8035μ0.0021 0.8720μ0.0017 26.567μ0.030 7.855μ0.0016 
 
1.085μ0.0045 
F5 0.8270μ0.0014 0.8676μ0.0017 23.434μ0.033 4.679μ0.0025 1.0490μ0.0066 
F6 0.7973μ0.0016 0.8633μ0.0016 
25.913μ0.026 7.645μ0.0036 1.0827μ0.0081 
F7 0.8106μ0.0008 0.8858μ0.0018 24.127μ0.056 8.489μ0.0043 1.0927μ0.0023 
            F8 0.8178μ0.0005 0.8820μ0.0023 23.974μ0.043 7.278μ0.0035 1.0785μ0.0013 
            F9 0.8090μ0.0018 0.8476μ0.0021 26.654μ0.034 4.554μ0.0043 
 
1.0477μ0.0034 
    All values are expressed as mean μS.D, n=3. 
 
Table 6: Friability and drug content results of Aceclofenac pellet 
Formulation code Friability (%) Drug content 
F1 0.34μ0.0332 96.6μ0.08 
F2 0.34μ0.0523 96.59μ0.043 
F3 0.39μ0.1312 95.50μ0.034 
F4 0.36μ0.1023 97.44μ0.25 
F5 0.39μ0.0645 96.04μ0.04 
F6 0.34μ0.1932 97.61μ0.08 
F7 0.37μ0.0523 96.37μ0.04 
F8 0.38μ0.0644   97.17μ0.023 
F9 0.39μ0.0434 96.27μ0.04 
All values are expressed as mean μS.D, n=3. 
Table 7:  Sieve analysis of optimized formulation (F8) 









under smaller sieve 
Weight size
Nxd 
16 1000 1000/pan 1000 0 0 0
20 710 710/1000 855 1 1 855
25 600 600/710 655 7 7 4585
30 500 500/600 550 89.5 89.5 49125
    (n) =100  (nd)= 54665
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                              %Cumulative release (Mean μS.D)
F1 F2 F3 F4 F5
0 0 0 0 0 0
0.25 2.33μ0.38 4.11μ0.23 3.21μ0.58 2.35μ0.36 2.56μ0.55
0.5 10.54μ0.65 12.26μ0.35 10.57μ0.65 8.24μ0.64 6.54μ0.35
0.75 16.25μ0.43 18.81μ0.47 16.43μ0.67 12.25μ0.43 9.68μ0.35
1 22.34μ0.35 24.23μ0.23 20.34μ0.35 17.12μ0.35 13.35μ0.31
2 34.62μ0.38 46.23μ0.24 41.24μ0.32 38.54μ0.34 32.24μ0.35
3 42.35μ0.51 63.65μ0.24 53.35μ0.45 50.21μ0.45 42.46μ0.54
4 - 74.65μ0.24 65.43μ0.35 61.22μ0.24 55.43μ0.35
5 - 86.24μ0.24 73.32μ0.24 70.22μ0.35 62.33μ0.41
6 - 93.31μ0.34 87.71μ0.33 79.21μ0.57 73.36μ0.43
8 - - 92.23μ0.34 81.11μ0.57 81.24μ0.35
10 - - - 87.23μ0.34 85.51μ0.47
All values are expressed as mean μS.D, n=6. 
 




%cumulative release (Mean μS.D)
F6 F7 F8 F9 
0 0 0 0 0 
0.25 3.91μ0.23 3.21μ0.45 2.65μ0.45 2.11μ0.22
0.5 9.24μ0.65 7.22μ0.54 6.14μ0.16 4.15μ0.55
0.75 16.45μ0.87 12.45μ0.65 10.45μ0.65 9.26μ0.24
1 20.43μ0.24 17.24μ0.35 15.23μ0.35 13.31μ0.34
2 41.24μ0.47 32.45μ0.35 26.21μ0.34 20.43μ0.47
3 55.21μ0.35 46.34μ0.45 41.21μ0.45 35.43μ0.45
4 69.21μ0.57 57.11μ0.21 53.55μ0.46 47.23μ0.46
5 81.56μ0.65 70.45μ0.46 61.13μ0.57 57.25μ0.35
6 92.21μ0.24 85.25μ0.24 72.16μ0.45 69.33μ0.76
8 - 90.21μ0.55 86.21μ0.54 78.22μ0.21
10 - - 96.43μ0.46 87.41μ0.35
All values are expressed as mean μS.D, n=6 
 
Stability studies 
The stability studies were carried out according to the ICH 
guidelines for the optimized formulation at 25ĈC/60%±5% RH, and 
40ĈC /75%±5% RH. The colour, shape, diameter and friability were 
white and spherical with the values 546.65øm, 0.36% respectively, 
after 3months study at their respective temperature and humidity. 
The drug content was found to be 96.19% at 6months study, initial 
it was 96.25%, after 1month 96.34%,3months 96.24% for 
25ĈC/60%±5% RH and the drug content was found to be as 
95.90% after 3 months, initially 96.26% 1month 96.21%, 
3months96.19%. The pellets maintained the similar property 
throughout the period. The in vitro data conducted for the optimized 
formulation after stability study the release pattern does not show 
more variation in results. This indicates that the prepared pellets 
(F8) are stable at accelerated storage conditions and are suitable 
for in vivo studies in animal models. 
Conclusion 
The present investigation was focused on the improvement of 
absorption and oral bioavailability of aceclofenac along with 
sustained action. To meet the above criteria sustained release 
pellets of aceclofenac were formulated with hydrophobic rate 
controlling polymers such as Ethylcellulose and Kollicoat SR-30D 
as key excipients. 
The hydrophobic polymers selected were more reliable as they 
released the drug slowly, extending it over a long period of time. 
Alternating concentrations of Kollicoat SR30D had a significant 
influence on the release profile of the drug. The in vitro dissolution 
profiles of F8 were found to be better formulation. Therefore, it may 
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be concluded that the sustained release formulations using 
suspension coating of aceclofenac on sugar spherules are suitable 
as sustained delivery to meet the pharmacological action for which 
it is intended. Further studies on the pellets to assure the behavior 
of release in in vivo would be a better approach. 
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